Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

NCT05284747 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05284747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05284747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Active, not recruiting
Start date
October 26, 2022
Completion date
May 29, 2027
Enrollment
6,019 (actual)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, coronary revascularization, myocardial infarction, stroke